Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) Depreciation & Amortization - Total (2019 - 2025)

Historic Depreciation & Amortization - Total for Akebia Therapeutics (AKBA) over the last 6 years, with Q3 2025 value amounting to $318000.0.

  • Akebia Therapeutics' Depreciation & Amortization - Total fell 1239.67% to $318000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year decrease of 1564.76%. This contributed to the annual value of $1.5 million for FY2024, which is 776.03% down from last year.
  • Akebia Therapeutics' Depreciation & Amortization - Total amounted to $318000.0 in Q3 2025, which was down 1239.67% from $316000.0 recorded in Q2 2025.
  • In the past 5 years, Akebia Therapeutics' Depreciation & Amortization - Total ranged from a high of $408000.0 in Q4 2022 and a low of $314000.0 during Q1 2025
  • Moreover, its 4-year median value for Depreciation & Amortization - Total was $379000.0 (2023), whereas its average is $366916.7.
  • In the last 5 years, Akebia Therapeutics' Depreciation & Amortization - Total surged by 75.57% in 2024 and then tumbled by 2100.0% in 2025.
  • Quarter analysis of 4 years shows Akebia Therapeutics' Depreciation & Amortization - Total stood at $408000.0 in 2022, then dropped by 3.43% to $394000.0 in 2023, then dropped by 14.97% to $335000.0 in 2024, then dropped by 5.07% to $318000.0 in 2025.
  • Its Depreciation & Amortization - Total stands at $318000.0 for Q3 2025, versus $316000.0 for Q2 2025 and $314000.0 for Q1 2025.